M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B BioPharma DiveAssertio s latest offer represents a roughly 31% premium over an initial acquisition proposal.Read full story pharminent May 13, 2026 (Last updated: May 13, 2026) BioPharma Dive Assertio s latest offer represents a roughly 31% premium over an initial acquisition proposal. Read full story Post navigation Previous: ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body compositionNext: UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026